Porous Silicon as a Platform for Radiation Theranostics Together with a Novel RIB-Based Radiolanthanoid

Ulrika Jakobsson, Ermei Mäkilä, Anu J. Airaksinen, Osku Alanen, Asénath Etile, Ulli Köster, Sanjeev Ranjan, Jarno Salonen, Hélder A. Santos, Kerttuli Helariutta

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Mesoporous silicon (PSi) is biocompatible and tailorable material with high potential in drug delivery applications. Here, we report of an evaluation of PSi as a carrier platform for theranostics by delivering a radioactive ion beam- (RIB-) based radioactive lanthanoid into tumors in a mouse model of prostate carcinoma. Thermally hydrocarbonized porous silicon (THCPSi) wafers were implanted with Dy-159 at the facility for radioactive ion beams ISOLDE located at CERN, and the resulting [Dy-159]THCPSi was postprocessed into particles. The particles were intratumorally injected into mice bearing prostate cancer xenografts. The stability of the particles was studied in vivo, followed by ex vivo biodistribution and autoradiographic studies. We showed that the process of producing radionuclide-implanted PSi particles is feasible and that the [Dy-159]THCPSi particles stay stable and local inside the tumor over seven days. Upon release of Dy-159 from the particles, the main site of accumulation is in the skeleton, which is in agreement with previous studies on the biodistribution of dysprosium. We conclude that THCPSi particles are a suitable platform together with RIB-based radiolanthanoids for theranostic purposes as they are retained after administration inside the tumor and the radiolanthanoid remains embedded in the THCPSi.

Original languageEnglish
Article number3728563
JournalContrast Media & Molecular Imaging
Volume2019
Number of pages9
ISSN1555-4309
DOIs
Publication statusPublished - 12 Mar 2019
MoE publication typeA1 Journal article-refereed

Fields of Science

  • BIOCOMPATIBILITY
  • DRUG-DELIVERY
  • FABRICATION
  • IN-VIVO
  • MESOPOROUS SILICON
  • MULTISTAGE DELIVERY
  • NANOPARTICLES
  • PARTICLES
  • SURFACE
  • THERAPY
  • 116 Chemical sciences
  • 114 Physical sciences
  • 317 Pharmacy

Cite this

Jakobsson, Ulrika ; Mäkilä, Ermei ; Airaksinen, Anu J. ; Alanen, Osku ; Etile, Asénath ; Köster, Ulli ; Ranjan, Sanjeev ; Salonen, Jarno ; Santos, Hélder A. ; Helariutta, Kerttuli. / Porous Silicon as a Platform for Radiation Theranostics Together with a Novel RIB-Based Radiolanthanoid. In: Contrast Media & Molecular Imaging. 2019 ; Vol. 2019.
@article{f6f15e4db3b44e08b4df12729692bca5,
title = "Porous Silicon as a Platform for Radiation Theranostics Together with a Novel RIB-Based Radiolanthanoid",
abstract = "Mesoporous silicon (PSi) is biocompatible and tailorable material with high potential in drug delivery applications. Here, we report of an evaluation of PSi as a carrier platform for theranostics by delivering a radioactive ion beam- (RIB-) based radioactive lanthanoid into tumors in a mouse model of prostate carcinoma. Thermally hydrocarbonized porous silicon (THCPSi) wafers were implanted with Dy-159 at the facility for radioactive ion beams ISOLDE located at CERN, and the resulting [Dy-159]THCPSi was postprocessed into particles. The particles were intratumorally injected into mice bearing prostate cancer xenografts. The stability of the particles was studied in vivo, followed by ex vivo biodistribution and autoradiographic studies. We showed that the process of producing radionuclide-implanted PSi particles is feasible and that the [Dy-159]THCPSi particles stay stable and local inside the tumor over seven days. Upon release of Dy-159 from the particles, the main site of accumulation is in the skeleton, which is in agreement with previous studies on the biodistribution of dysprosium. We conclude that THCPSi particles are a suitable platform together with RIB-based radiolanthanoids for theranostic purposes as they are retained after administration inside the tumor and the radiolanthanoid remains embedded in the THCPSi.",
keywords = "BIOCOMPATIBILITY, DRUG-DELIVERY, FABRICATION, IN-VIVO, MESOPOROUS SILICON, MULTISTAGE DELIVERY, NANOPARTICLES, PARTICLES, SURFACE, THERAPY, 116 Chemical sciences, 114 Physical sciences, 317 Pharmacy",
author = "Ulrika Jakobsson and Ermei M{\"a}kil{\"a} and Airaksinen, {Anu J.} and Osku Alanen and As{\'e}nath Etile and Ulli K{\"o}ster and Sanjeev Ranjan and Jarno Salonen and Santos, {H{\'e}lder A.} and Kerttuli Helariutta",
year = "2019",
month = "3",
day = "12",
doi = "10.1155/2019/3728563",
language = "English",
volume = "2019",
journal = "Contrast Media & Molecular Imaging",
issn = "1555-4317",
publisher = "WILEY-HINDAWI",

}

Porous Silicon as a Platform for Radiation Theranostics Together with a Novel RIB-Based Radiolanthanoid. / Jakobsson, Ulrika; Mäkilä, Ermei; Airaksinen, Anu J.; Alanen, Osku; Etile, Asénath; Köster, Ulli; Ranjan, Sanjeev; Salonen, Jarno; Santos, Hélder A.; Helariutta, Kerttuli.

In: Contrast Media & Molecular Imaging, Vol. 2019, 3728563, 12.03.2019.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Porous Silicon as a Platform for Radiation Theranostics Together with a Novel RIB-Based Radiolanthanoid

AU - Jakobsson, Ulrika

AU - Mäkilä, Ermei

AU - Airaksinen, Anu J.

AU - Alanen, Osku

AU - Etile, Asénath

AU - Köster, Ulli

AU - Ranjan, Sanjeev

AU - Salonen, Jarno

AU - Santos, Hélder A.

AU - Helariutta, Kerttuli

PY - 2019/3/12

Y1 - 2019/3/12

N2 - Mesoporous silicon (PSi) is biocompatible and tailorable material with high potential in drug delivery applications. Here, we report of an evaluation of PSi as a carrier platform for theranostics by delivering a radioactive ion beam- (RIB-) based radioactive lanthanoid into tumors in a mouse model of prostate carcinoma. Thermally hydrocarbonized porous silicon (THCPSi) wafers were implanted with Dy-159 at the facility for radioactive ion beams ISOLDE located at CERN, and the resulting [Dy-159]THCPSi was postprocessed into particles. The particles were intratumorally injected into mice bearing prostate cancer xenografts. The stability of the particles was studied in vivo, followed by ex vivo biodistribution and autoradiographic studies. We showed that the process of producing radionuclide-implanted PSi particles is feasible and that the [Dy-159]THCPSi particles stay stable and local inside the tumor over seven days. Upon release of Dy-159 from the particles, the main site of accumulation is in the skeleton, which is in agreement with previous studies on the biodistribution of dysprosium. We conclude that THCPSi particles are a suitable platform together with RIB-based radiolanthanoids for theranostic purposes as they are retained after administration inside the tumor and the radiolanthanoid remains embedded in the THCPSi.

AB - Mesoporous silicon (PSi) is biocompatible and tailorable material with high potential in drug delivery applications. Here, we report of an evaluation of PSi as a carrier platform for theranostics by delivering a radioactive ion beam- (RIB-) based radioactive lanthanoid into tumors in a mouse model of prostate carcinoma. Thermally hydrocarbonized porous silicon (THCPSi) wafers were implanted with Dy-159 at the facility for radioactive ion beams ISOLDE located at CERN, and the resulting [Dy-159]THCPSi was postprocessed into particles. The particles were intratumorally injected into mice bearing prostate cancer xenografts. The stability of the particles was studied in vivo, followed by ex vivo biodistribution and autoradiographic studies. We showed that the process of producing radionuclide-implanted PSi particles is feasible and that the [Dy-159]THCPSi particles stay stable and local inside the tumor over seven days. Upon release of Dy-159 from the particles, the main site of accumulation is in the skeleton, which is in agreement with previous studies on the biodistribution of dysprosium. We conclude that THCPSi particles are a suitable platform together with RIB-based radiolanthanoids for theranostic purposes as they are retained after administration inside the tumor and the radiolanthanoid remains embedded in the THCPSi.

KW - BIOCOMPATIBILITY

KW - DRUG-DELIVERY

KW - FABRICATION

KW - IN-VIVO

KW - MESOPOROUS SILICON

KW - MULTISTAGE DELIVERY

KW - NANOPARTICLES

KW - PARTICLES

KW - SURFACE

KW - THERAPY

KW - 116 Chemical sciences

KW - 114 Physical sciences

KW - 317 Pharmacy

U2 - 10.1155/2019/3728563

DO - 10.1155/2019/3728563

M3 - Article

VL - 2019

JO - Contrast Media & Molecular Imaging

JF - Contrast Media & Molecular Imaging

SN - 1555-4317

M1 - 3728563

ER -